EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 18 / No 3 (Mars 2002) Med Sci (Paris), 18 3 (2002) 357-361 References
Free Access
Issue
Med Sci (Paris)
Volume 18, Number 3, Mars 2002
Page(s) 357 - 361
Section M/S Revues : Mini-Synthèses
DOI https://doi.org/10.1051/medsci/2002183357
Published online 15 March 2002
  1. Piton A, Poynard T, Imbert-Bismut F, et al. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. Hepatology 1998; 27 : 1217–9. [Google Scholar]
  2. Pillonel J, Laperche S. Surveillance des marqueurs d’une infection par le VIH, l’HTLV et les virus des hépatites B et C chez les donneurs de sang en France de 1991 à 2000. Bull Epidemiol Hebdo 2001; 46 : 207–9. [Google Scholar]
  3. McGuinness PH, Bishop GA, Lien A, Wiley B, Parsons C, McCaughan. Detection of serum hepatitis C virus RNA Fleming KA. Liver histology in hepatitis C infection: a comparison between patients with persistently normal or abnormal transaminases. Gut 1995; 37 : 274–8. [Google Scholar]
  4. Prieto M, Olaso V, Verdu C, et al. Does the healthy hepatitis C virus carrier state really exist? An analysis using polymerase chain reaction. Hepatology 1995; 22 : 413–7. [Google Scholar]
  5. Shakil AO, Conry-Cantilena C, Alter HJ, et al. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. Ann Intern Med 1995; 123 : 330–7. [Google Scholar]
  6. Gholson CF, Morgan K, Catinis G, et al. Chronic hepatitis C with normal aminotransferase levels. A clinical histologic study. Am J Gastroenterol 1997; 92 : 1788–92. [Google Scholar]
  7. Mathurin P, Moussalli J, Cadranel JF, et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998; 27 : 868–72. [Google Scholar]
  8. Jamal MM, Soni A, Quinn PG, Wheeler DE, Arora S, Johnston DE. Clinical features of hepatitis Cinfected patients with persistently normal alanine transaminase levels in the Southwestern United States. Hepatology 1999; 30 : 1307–11. [Google Scholar]
  9. Persico M, Persico E, Suozzo R, et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 2000; 118 : 760–4. [Google Scholar]
  10. Shiffman ML, Stewart CA, Hofmann CM, et al. Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: comparison of hepatic histology an response to interferon therapy. J Infect Dis 2000; 182 : 1595–601. [Google Scholar]
  11. Healey CJ, Chapman RW, Fleming KA. Liver histology in hepatitis C infection: a comparison between patients with persistently normal or abnormal transaminases. Gut 1995; 37: 274–8. [Google Scholar]
  12. Shindo M, Arai K, Sokawa Y, Okuno T. The virological and histological states of antihepatitis C virus-positive subjects with normal liver biochemical values. Hepatology 1995; 22 : 418–25. [Google Scholar]
  13. Marcellin P, Kilani A, Cymes K, et al. Virological and histological characteristics in anti-HCV positive subjects with normal transaminase levels (abstract). Hepatology 1995; 22 : 273A. [Google Scholar]
  14. Tassopoulos NC. Treatment of patients with chronichepatitis C and normal ALT levels. J Hepatol 1999; 31 (suppl 1) : 193–6. [Google Scholar]
  15. Rossini A, Ravaggi A, Biasi L, et al. Virological response to interferon treatment in hepatitis C virus carriers with normal aminotransferase levels and chronic hepatitis. Hepatology 1997; 26 : 1012–7. [Google Scholar]
  16. Marcellin P, Lévy S, Erlinger S. Therapy of hepatitis C: patients with normal aminotransferase levels. Hepatology 1997; 26 (suppl 1) : 133S–136S. [Google Scholar]
  17. Nutt AK, Hassan HA, Lindsey J, Lamps LW, Raufman JP. Liver biopsy in the evaluation of patients with chro-nic hepatitis C who have repeatedly normal or nearnormal serum alanine aminotransferase levels. Am J Med 2000; 109 : 62–4. [Google Scholar]
  18. EASL International Consensus Conference on Hepatitis C. Consensus statement. J Hepatol 1999; 30 : 956–61. [Google Scholar]
  19. Serfaty L, Chazouillères O, Pawlotsky JM, Andreani T, Pellet C, Poupon R. Interferon alpha therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity. Gastroenterology 1996; 110 : 291–5. [Google Scholar]
  20. Areias J, Pedroto I, Freitas T, et al. Hepatitis C virus carriers with normal ALT activity: viremia, genotype and effect of interferon therapy (abstract). Gastroenterology 1996; 110 : 1144A. [Google Scholar]
  21. Ideo G, Bellobuono A, Temprini S, Mondazzi L, Bellati G, Zanetti AR. Poor efficacy of alpha-interferon treatment in patients affected by chronic hepatitis C with normal or near normal ALT levels (abstract). Gastroenterology 1996; 110 : 1215A. [Google Scholar]
  22. Silverman AL, Piquette DL, Filipiak CL, Neill JS, Bayati N, Gordon SC. Alfa-interferon treatment of hepatitis C virus RNA-positive patients with normal or nearnormal levels. Am J Gastroenterol 1997; 92 : 1793–5. [Google Scholar]
  23. Nordoy I, Krarup HB, Bell H, et al. Interferon-alpha 2b therapy in low–activity hepatitis C: a pilot study. Scand J Gastroenterol 1997; 32 : 1256–60. [Google Scholar]
  24. Sangiovanni A, Morales R, Spinzi GC, et al. Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: a pilot randomized controlled study. Hepatology 1998; 27 : 853–6. [Google Scholar]
  25. Orito E, Mizokami M, Suzuki K, et al. Interferon alpha therapy for individuals with normal serum ALT before treatment. J Gastroenterol Hepatol 1996; 12 : 58–61. [Google Scholar]
  26. Hézode C, Roudot-Thoraval F , Capron D, et al. Alpha 2A interferon monotherapy in patient with chronic hepatitis C and repeatedly normal aminotransferase levels (abstract). Hepatology 2000;32 : 352A. [Google Scholar]
  27. Tran A, Longo F, Ouzan D, et al. Effects of 1-year Interferon-alpha 2a treatment for patients with chronic hepatitis C and persistently normal transaminase activity. Scand J Gastroenterol 2000; 4 : 433–7. [Google Scholar]
  28. Van Thiel DH, Caraceni P, Molloy PJ, et al. Chronic hepatitis C in patients with normal or near normal alanine aminotransferase levels: the role of interferon alpha 2b therapy. J Hepatol 1995; 23 : 503–8. [Google Scholar]
  29. Hézode C, Roudot-Thoraval F, Capron D, et al. Histological evaluation of alpha 2a interferon monotherapy in patients with chronic hepatitis C and repeatedly normal aminotransferase levels. A randomized study (abstract). J Hepatol 2001; 34 (suppl 1) : 4A. [Google Scholar]
  30. Lee SS, Sherman M. Pilot study of interferon-a and ribavirin treatment in patients with chronic hepatitis C and normal transaminase values. J Viral Hep 2001; 8 : 202–5. [Google Scholar]
  31. Gordon SC, Fang JWS, Silverman AL, MCHutchison JG, Albrecht JK. The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C. Hepatology 2000; 32 : 400–4. [Google Scholar]
  32. Dhumeaux D, Hézode C, Fried MW, et al. Effets de l’interféron alpha 2a pégylé (Pégasys) associé à la ribavirine dans l’hépatite chronique virale C. Étude randomisée multicentique (abstract). Gastroenterol Clin Biol 2001; 25 : 617A. [Google Scholar]
  33. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358 : 958–65. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.